Agonistas do receptor de GLP-1 no emagrecimento estético
Revista Ciências da Saúde Ceuma · 13.03.2026 · 4 (1) · 1-11
DOI: 10.61695/rcs.v4i1.94 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Ciências da Saúde Ceuma, online erschienen am 13.03.2026. Verfasst von Ana Beatriz Caetano Peixoto de Camargo und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, has expanded beyond approved clinical indications and is increasingly reported in aesthetic weight loss practices. This narrative review aimed to analyze the scientific literature regarding efficacy, adverse effects, and ethical implications of the off-label use of these medications in healthy individuals. Twelve articles published over the past ten years were selected using the Connected Papers platform, addressing mechanisms of action, clinical outcomes, and safety profiles. The findings indicate high efficacy in weight reduction and cardiometabolic improvement among individuals with established therapeutic indications; however, no evidence was identified regarding efficacy or safety in normoweight populations. Gastrointestinal symptoms were the most frequently reported adverse effects and were generally mild and transient; serious events were rare, although potential risks may be underestimated in healthy individuals. Ethical and social concerns related to the medicalization of aesthetic weight loss were also identified, including self-medication, inappropriate use, and inequitable access. In conclusion, the aesthetic use of GLP-1 receptor agonists lacks scientific support and may pose avoidable health risks. Further studies are needed to evaluate safety, social determinants, and the influence of digital media, as well as to support health education strategies and ethical prescribing guidelines.
Zitieren
APA
Camargo, A. B. C. P. D., Cândido, D. D. C., Matos, K. B., Pereira, M. E. C. L. D. A., Campos, M. E. R. S., Navarrete, P. P., & Oliveira, T. R. S. D. (2026). Agonistas do receptor de GLP-1 no emagrecimento estético. Revista Ciências da Saúde Ceuma, 4(1), 1-11. https://doi.org/10.61695/rcs.v4i1.94
Vancouver
Camargo ABCPD, Cândido DDC, Matos KB, Pereira MECLDA, Campos MERS, Navarrete PP, et al. Agonistas do receptor de GLP-1 no emagrecimento estético. Revista Ciências da Saúde Ceuma. 2026;4(1):1-11. doi:10.61695/rcs.v4i1.94
BibTeX
@article{Camargo2026,
author = {Camargo, Ana Beatriz Caetano Peixoto de and Cândido, Damares de Campos and Matos, Katharine Bianchini and Pereira, Maria Eduarda Carricondo Leite de Almeida and Campos, Maria Eduarda Romero Siqueira and Navarrete, Patrícia Palma and Oliveira, Thais Ranielle Souza de},
title = {Agonistas do receptor de GLP-1 no emagrecimento estético},
journal = {Revista Ciências da Saúde Ceuma},
year = {2026},
volume = {4},
number = {1},
pages = {1--11},
doi = {10.61695/rcs.v4i1.94}
}
EUVIMED